Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The highest odds for having bladder cancer following SH infection were observed among individuals with the CC genotypes for both NQO1 and SOD2 (OR [CI 95%] = 4.41 [2.32-8.38]).
|
24035474 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly increased BC risk of 1.8 (95% CI = 1.1-2.9).
|
24315573 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer.
|
23873104 |
2013 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggests that NQO1 C609T polymorphism is associated with bladder cancer susceptibility.
|
23749485 |
2013 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that NQO1 rs1800566 genetic polymorphism may contribute to bladder cancer development, especially in Asians.
|
23464456 |
2012 |
Bladder Neoplasm
|
0.600 |
Therapeutic
|
disease |
RGD |
Compared to the control group, a more preventive effect of SPUE and PPS treatment on bladder cancer was discovered, higher mRNA upregulation of GSTpi and NQO1 was seen in the treatment group.
|
21213404 |
2011 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results of this study strongly suggest that the variant allele of NQO1 (Pro187Ser) may affect individual susceptibility to bladder cancer, particularly among smokers, in this ethnic Kashmiri population.
|
21253823 |
2011 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Intraperitoneal ovarian metastases and bladder tumor clinical samples were analyzed for NQO1 and NQO2 activity, mRNA expression by semiquantitative reverse transcription-PCR, and genotype by RFLP analysis.
|
17332305 |
2007 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our data are consistent with the notion that NQO1 polymorphisms influence the course and clinical outcomes of urinary bladder neoplasms.
|
17469025 |
2007 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of glutathione S-transferase (GST) enzymes (M1, T1), methylenetetrahydrofolate (MTHFR) 677 and 1298, and the NAD(P)H:quinone oxidoreductase (NQO1) polymorphisms in a population-based bladder cancer case-control study in Argentina.
|
15219943 |
2004 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk.
|
14729580 |
2004 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The relationship between NQO1 activity and cellular response to MMC is however controversial and the aim of this study was to determine whether the response of bladder cancer patients to MMC can be forecast on the basis of NQO1*2 genotype status.
|
15375541 |
2004 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The variant allele genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (odds ratio (OR)=1.51; 95% confidence interval (CI)=1.01-2.25).
|
12694753 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The variant allele genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (odds ratio (OR)=1.51; 95% confidence interval (CI)=1.01-2.25).
|
12694753 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the sensitivity of patient bladder tumors to MMC is correlated with the expression of DTD and P450R in tumors and suggest that the lower expression of these enzymes in the high-grade and more invasive tumors is a cause of the lower efficacy of intravesical MMC in these tumors.
|
11350900 |
2001 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
|
8631603 |
1996 |